Deal signals plans for ‘sustainable’ bio-synthesised CBD

The commercialisation of bio-synthesised cannabidiol could be on the horizon following the announcement by Amyris that it will be forming a new partnership to focus on “cannabinoid development”. The California-based company is best known for creating synthetic sweeteners and medicines from sugars using a yeast-based process, and it is thought it will do the same with CBD. While the company » Continue Reading.
Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization